Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Paclitaxel Trevatide | ANG1005|GRN1005 | Chemotherapy - Taxane 3 | Paclitaxel Trevatide (GRN1005) consists of paclitaxel bound to a peptide that binds LRP-1, which allows the drug-peptide conjugate to cross the blood-brain barrier and delivers paclitaxel to LRP-1 expressing tumor cells (PMID: 22203732, PMID: 23349317). | |
trastuzumab and hyaluronidase-oysk injection | Herceptin Hylecta | HER2 (ERBB2) Antibody 76 | Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is an injectable formulation consists of Herceptin (trastuzumab) and hyaluronidase, which demonstrates anti-tumor activity against ERBB2 (HER2)-positive breast cancer (PMID: 28625777). Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) is FDA-approved for use in patients with Erbb2 (Her2)-overexpressing and/or Erbb2 (Her2) amplified breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05256225 | Phase II | Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Recruiting | USA | 1 |